7.2. localised high-risk disease. 7.2.1. radical nephroureterectomy 7.2.1.1. surgical approach 7.2.1.1.1. open radical nephroureterectomy open rnu bladder cuff excision standard treatment high-risk utuc, regardless tumour location . radical nephroureterectomy must performed according oncological principles preventing tumour seeding . section 7.2.5 lists recommendations rnu. 7.2.1.1.2. minimal invasive radical nephroureterectomy retroperitoneal metastatic dissemination metastasis along trocar pathway following manipulation large tumours pneumoperitoneal environment may occur . several precautions may lower risk tumour spillage: avoid entering urinary tract, except performing bladder cuff excision prior clipping ureter complete drainage bladder;avoid direct contact instruments tumour;perform procedure closed system. avoid morcellation tumour use endobag tumour extraction;the kidney ureter must removed en bloc bladder cuff;in invasive large (t3/t4 and/or n+/m+) tumours open approach favoured, oncological outcomes may better compared minimally-invasive rnu . laparoscopic rnu safe experienced hands adhering strict oncological principles. tendency towards equivalent oncological outcomes laparoscopic vs. open rnu [230,233-236]. one prospective randomised study shown laparoscopic rnu inferior open rnu non-organ- confined utuc. however, small trial (n = 80) . oncological outcomes rnu changed significantly past three decades despite staging surgical refinements . population-based data set, hospital volume > 6 patients per year treated rnu showed improvement short-term outcomes (30- 90-day mortality) overall long-term survival . robot-assisted laparoscopic approach considered allowing comparable peri operative benefit standard laparoscopic surgery [239-241], data suggesting oncologic equivalence approaches [242-244]; however, risk intravesical recurrence may increased laparoscopic robotic rnu compared open approach . 7.2.1.1.3. bladder cuff management resection distal ureter orifice performed considerable risk tumour recurrence area bladder [22,216,246-248]. several techniques considered simplify distal ureter resection, including pluck technique, stripping, transurethral resection intramural ureter, intussusception. none techniques convincingly shown equal complete bladder cuff excision . 7.2.1.1.4. lymph node dissection use lnd template likely greater impact patient survival number removed lns . template-based completeness lnd improves css patients muscle-invasive disease reduces risk local recurrence . even clinically pathologically node-negative patients, lnd improves survival. risk ln metastasis increases advancing tumour stage . lymph node dissection appears unnecessary cases tat1 utuc low risk ln metastasis [253-256], however, tumour staging inaccurate pre-operatively; therefore template-based lnd offered patients scheduled rnu high-risk utuc. templates lnd described . 7.2.2. distal ureterectomy distal ureterectomy high-risk utuc distal ureter seems associated similar oncological outcomes rnu . procedure performed concomitant ln dissection. however, given low level evidence, approach currently used highly selected cases benefits may greater potential risks. 7.2.3. kidney-sparing surgery imperative indications kidney-sparing surgery, including ureteroscopy segmental ureterectomy, considered case-by- case basis patients high-risk utuc imperative indications solitary kidney, bilateral utuc, severe chronic kidney disease comorbidity compromising use rnu. however, greater risk progression kidney-sparing surgery high- vs. low-risk utuc direct impact survival . 7.2.4. peri-operative chemotherapy 7.2.4.1. neoadjuvant treatments 7.2.4.1.1. chemotherapy primary advantage neoadjuvant chemotherapy (nac) ability give cisplatin-based regimens patients still maximal renal function. several retrospective studies evaluating role nac shown evidence pathological downstaging complete response rates rnu [180,260-263] direct impact os . furthermore, nac shown result lower disease recurrence- mortality rates compared rnu alone, without compromising use definitive surgical treatment potential os benefit [262,264-266]. rcts published yet prospective data phase ii trials showed nac based cisplatin combination therapy associated 14 - 19% pathological complete response rate high-grade and/or ct2-t4n0m0 utuc . addition, final pathological stage < ypt1 60% included patients acceptable toxicity profile. systematic review meta-analysis comprising 800 patients, nac shown pathologic partial response 43% downstaging 33% patients, resulting os css survival benefit compared rnu alone . however, important note evidence meta-analysis conclusive, given significant bias heterogeneity available data lack distinction truly neoadjuvant downstaging chemotherapy. 7.2.4.1.2. immunotherapy small phase ii study including 10 patients high-risk utuc evaluated efficacy pembrolizumab neoadjuvant setting . however, pathological response observed one treatment-related death reported. thus, currently evidence support use neoadjuvant immunotherapy high-risk utuc. 7.2.4.2. adjuvant treatments 7.2.4.2.1. bladder instillations rate bladder recurrence rnu utuc 22–47% . two prospective randomised trials two meta-analyses demonstrated single post-operative dose intravesical chemotherapy (mitomycin c, pirarubicin) 2–10 days surgery reduces risk bladder tumour recurrence within first years post-rnu patients without history bc. prior instillation, cystogram considered case concerns drug extravasation. studies showed low risk adverse events. intravesical chemotherapy also safely given time rnu prior bladder cuff opening, removing need post- operative cystogram, low level data efficacy . based current evidence unlikely additional instillations beyond one peri-operative instillation chemotherapy substantially reduce risk intravesical recurrence . whilst direct evidence supporting use intravesical chemotherapy instillation chemotherapy kidney-sparing surgery, single- dose chemotherapy might also effective setting well. management outlined figures 7.1 7.2. one low-level evidence study suggested bladder irrigation might reduce risk bladder recurrence rnu . 7.2.4.2.2. systemic chemotherapy phase iii multicentre prospective rct (n = 261) evaluating benefit four cycles adjuvant gemcitabine-platinum combination chemotherapy initiated within 90 days rnu vs. surveillance reported significant improvement disease-free survival (dfs) patients pt2–pt4, n (any) positive (pt any, n1–3) m0 utuc (3 year dfs 71% vs 50%; 5 year dfs 63% vs 46%. hr 0.54 ; ci 0.36-0.79; 3 & 5 year mfs 19 % improvement hr 0.55 ci 0.0.36-0.77) . patients stratified gemcitabine/cisplatin gemcitabine/carboplatin chemotherapy based gfr alone benefit seen irrespective chemotherapy type. non-significant trend towards improved os (12% 3 years) study met primary endpoint 3 year dfs, closed early, leaving underpowered secondary endpoint os. main potential limitation using adjuvant chemotherapy concern renal function may deteriorate rnu precluding cisplatin use patients could benefit . review peri-operative predictors decline renal function rnu showed three month gfr levels around 50 mls/min . split dose hydration cisplatin may considered patients gfr 45 ml/min. table 2 outlines eligibility criteria platinum chemotherapy. retrospective study histological subtypes utuc exhibit different survival rates adjuvant chemotherapy associated os benefit patients pure uc . however, whilst histological subtypes utuc exhibit different survival rates retrospective studies, adjuvant chemotherapy considered uc dominant pathology. table 2: definitions platinum-eligibility systemic treatment urothelial carcinoma. platinum-eligibleplatinum-ineligiblecisplatin-eligiblecarboplatin*-eligibleecog ps 0-1 andgfr > 50–60 ml/min andaudiometric hearing loss grade < 2 andperipheral neuropathy grade < 2 andcardiac insufficiency nyha class < iiiecog ps 2 gfr 30–60 ml/minor fulfilling cisplatin-eligibility criteriaany following:gfr < 30ml/minecog ps > 2ecog ps 2 gfr < 60ml/mincomorbidites > grade 2 * carboplatin indicated neoadjuvant treatment 7.2.4.2.3. immunotherapy phase iii, multicentre, double-blind rct involving patients high-risk muscle-invasive uc undergone radical surgery (pt3, pt4a, pn+), adjuvant nivolumab improved dfs compared placebo intention-to-treat population (20.8 vs. 10.8 months) among patients programmed death-ligand 1 (pd-l1) expression level 1% . patient population predominantly consisted bc patients post- radical cystectomy, additional smaller cohort patients utuc post-rnu. median recurrence-free survival outside urothelial tract entire intention-to-treat population 22.9 months nivolumab 13.7 months placebo. treatment-related adverse events > grade 3 occurred 17.9% nivolumab group 7.2% placebo group. subgroup analysis, patients utuc included study seem benefit adjuvant nivolumab, requires follow-up analysis. nonetheless, european medicines agency (ema) approved nivolumab monotherapy adjuvant treatment patients muscle-invasive uc tumour cell pd-l1 expression > 1%, high risk recurrence radical surgery decline unfit adjuvant chemotherapy . network meta-analysis suggests superior oncological benefit adjuvant platinum-based chemotherapy immune checkpoint inhibitors patients treated radical surgery utuc . 7.2.4.2.4. radiotherapy adjuvant radiation therapy suggested control loco-regional disease surgical removal. data remains controversial insufficient conclusions [286-289]. moreover, added value chemotherapy remains questionable . 7.2.5. summary evidence recommendations management high-risk non-metastatic utuc summary evidenceleradical nephroureterectomy standard treatment high-risk utuc, regardless tumour location.2aopen, laparoscopic robotic approaches similar oncological outcomes organ-confined utuc.2afailure completely remove bladder cuff increases risk bc recurrence.3lymphadenectomy improves survival muscle-invasive utuc.3post-operative platinum-based adjuvant chemotherapy improves disease-free survival.1bsingle post-operative intravesical instillation chemotherapy lowers bc recurrence rate.1b recommendationsstrength ratingperform radical nephroureterectomy (rnu) patients high-risk non-metastatic upper tract urothelial carcinoma (utuc).strongperform open rnu non-organ confined utuc.weakperform template-based lymphadenectomy patients high-risk non-metastatic utuc.weakoffer adjuvant platinum-based chemotherapy rnu eligible patients pt2–t4 and/or pn+ disease.strongdeliver post-operative bladder instillation chemotherapy lower intravesical recurrence rate patients without history bc.strongdiscuss adjuvant nivolumab patients unfit for, declined, platinum-based adjuvant chemotherapy > pt3 and/or pn+ disease previous rnu alone > ypt2 and/or ypn+ disease previous neoadjuvant chemotherapy, followed rnu.weakoffer distal ureterectomy selected patients high-risk tumours limited distal ureter.weakdiscuss kidney-sparing management high-risk patients imperative indication case- by-case basis, shared-decision making process patient despite higher risk disease progression.strong figure 7.1: proposed flowchart management utuca: patients solitary kidney consider conservative approach.b: low-grade patients without invasive features consider conservative approach.ctu = computed tomography urography; rnu = radical nephroureterectomy; utuc = upper urinary tract urothelial carcinoma. figure 7.2: surgical treatment according location risk statusa: patients solitary kidney consider conservative approach.b: low-grade patients without invasive features consider conservative approach.1 = first treatment option; 2 = secondary treatment option.*in case amendable endoscopic management.lnd = lymph node dissection; rnu = radical nephroureterectomy; urs = ureteroscopy; utuc = upper urinary tract urothelial carcinoma.